Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthern Jiangsu People's Hospital
About this trial
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Eligibility criteria
Qualifiers
A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
Portal hypertension bleeding .
Splenomegaly with secondary hypersplenism.
No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
Disqualifiers
Hepatocellular carcinoma or any other malignancy.
Hypercoagulable state other than the liver disease related.
DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
Child - Pugh C
Trial design
Treatments tested in this trial
- Apixaban 2.5 MG
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov